key: cord-0258845-ut31tcsi
authors: Madden, D. E.; Olagoke, O.; Baird, T.; Neill, J.; Ramsay, K. A.; Fraser, T. A.; Bell, S. C.; Sarovich, D. S.; Price, E. P.
title: Express yourself: Quantitative real-time PCR assays for rapid chromosomal antimicrobial resistance detection in Pseudomonas aeruginosa
date: 2022-02-04
journal: nan
DOI: 10.1101/2022.02.03.22270419
sha: bf7eec4583692636492630fadc83238426a4473a
doc_id: 258845
cord_uid: ut31tcsi

The rise of antimicrobial-resistant (AMR) bacteria is a global health emergency. One critical facet in tackling this epidemic is more rapid AMR diagnosis in serious multi-drug resistant pathogens like Pseudomonas aeruginosa. Here, we designed and then validated two multiplex quantitative real-time PCR (qPCR) assays to simultaneously detect differential expression of the resistance-nodulation-division efflux pumps MexAB-OprM, MexCD-OprJ, MexEF-OprN, MexXY-OprM, the AmpC {beta}-lactamase, and the porin OprD, which are commonly associated with chromosomally-encoded AMR. Next, qPCRs were tested on 15 sputa from 11 participants with P. aeruginosa respiratory infections to determine AMR profiles in vivo. We confirm multiplex qPCR testing feasibility directly on sputa, representing a key advancement in in vivo AMR diagnosis. Notably, comparison of sputa with their derived isolates grown in Luria-Bertani broth (+2.5% NaCl) or a 5-antibiotic cocktail showed marked expression differences, illustrating the difficulty in replicating in vivo expression profiles in vitro. Cystic fibrosis sputa showed significantly reduced mexE and mexY expression when compared with chronic obstructive pulmonary disease sputa, despite harbouring fluoroquinolone- and aminoglycoside-resistant strains, indicating that these loci are not contributing to AMR in vivo. Sputum ampC expression was highest in participants receiving carbapenems (6.7-15x), some of whom were simultaneously receiving cephalosporins, the latter of which would be rendered ineffective by the upregulated ampC. Our qPCR assays provide valuable insights into the P. aeruginosa resistome, and their use on clinical specimens will permit timely treatment alterations that will improve patient outcomes and antimicrobial stewardship measures.

, the latter of which enabled gene expression comparison among 172 sputa, and between sputa and derived isolates. SCHI0070_D2 COPD sputum was chosen for 173 normalisation as this participant had no recent history of anti-pseudomonal antibiotic treatment, its 174 derived isolate, SCHI0070.S.1, was sensitive towards all 11 anti-pseudomonal antibiotics (Table 1) , 175 and there was good gene expression across all seven loci for this sample. For AMR loci lacking 176 detectable PCR amplification, a CT value of 45 was assigned to permit visualisation of genes with very 177 low/no expression. According to previously defined criteria (23), strains were regarded as hyper-178 producers if their AMR loci exhibited >10-fold higher expression compared with PAO1, except for 179 mexB and mexY, which were considered hyper-producing if >3-fold higher expression than PAO1 (23, 180 34, 38) . 181 AMR prediction from genomes. In silico AMR prediction for 16 genome-sequenced isolates, plus 182 PAO1 (Table 1) , was carried out using the P. aeruginosa-specific database in ARDaP v1.9 (59) 183 (available at: https://github.com/dsarov/ARDaP). The genomes of 14 strains have been previously 184 published (13); paired-end Illumina genomes for SCHI0065.S.1 and SCHI0070.S.1 were generated in 185 the current study and appended to NCBI BioProject PRJNA761496. We did not sequence 186 SCHI0018.S.11, SCHI0038.S.2, or SCHI0038.S.4 as these data were not considered essential for study 187 outcomes. 188 Statistical analysis. Gene expression differences were assessed using a two-way analysis of variance 189 test and Tukey's multiple comparison test using GraphPad Prism (GraphPad Software Inc., CA, USA). 190

Corrected p values of <0.05 were considered significant. 191 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270419 doi: medRxiv preprint

Multiplex qPCR assay performance. To assess assay sensitivity, LoD and LoQ values were 193 determined using a 10-fold DNA dilution series (40 ng to 0.04 fg). The LoD for all assays was 400 fg 194 (59 GEs), the LoQ for mexB, mexE and mexC was 400fg (59 GEs), and the LoQ for rpsL, ampC, mexY 195 and oprD was 4000 fg (587 GEs) (Figures S1 and S2). 196 Antibiotic susceptibility profiles. Testing towards 11 anti-pseudomonal antibiotics identified much 197 higher rates of AMR (range: 0-9 antibiotics) and MDR (10/12 strains) in CF-derived isolates when 198 compared with COPD-derived isolates (range: 0-2 antibiotics; 0/7 MDR strains) ( Table 1 ). This was 199 consistent with much greater antibiotic use in the CF cohort (Table 1 ) (40). The lowest susceptibility 200 rates were towards cefepime (0% CF and 100% COPD) and piperacillin (33% CF and 100% COPD), 201 whereas all 19 strains were susceptible to colistin and polymyxin B (Table 1) . Interestingly, cefepime 202 is rarely used for CF treatment at TPCH, indicating probable cross-resistance towards this antibiotic 203 in all CF-derived isolates. None of the participants were receiving polymyxins; as such, no AMR was 204 expected towards these antibiotics. 205

In silico AMR prediction. Genomic analysis of the derived P. aeruginosa isolates revealed a much 206 greater number of AMR determinants in the CF-derived strains (Table 1) . Although some AMR 207 determinants were identified in COPD isolates, none were associated with dysregulated expression 208 of the six AMR loci. In contrast, many CF-derived isolates encoded mutations predicted to alter gene 209 expression of our qPCR gene targets (Table 1) . Specifically, ampC overexpression was predicted in 210 SCHI0030.S.2 and SCHI0030.S.3 due to AmpD regulator loss (P42fs) (60); mexAB-oprM 211 overexpression was predicted in SCHI0002.S.9 and SCHI0002.S.12 due to a D187H missense 212 mutation in the NalD regulator (61); and mexCD-oprJ overexpression was predicted in SCHI0030.S.4 213 due to NfxB regulator loss (F126fs) (62). No mutations associated with mexEF-oprN or mexXY-oprM 214 overexpression were identified. Although not associated with gene expression changes, oprD loss 215 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Figure S3 ), LB+NaCl (n=14; Figure S4 ), or a 230 5-antibiotic cocktail (n=2; Figure S5 ) was assessed. All qPCR targets exhibited expression in at least 231 one strain; however, in some strains, particularly the CF-derived isolates, certain genes exhibited no 232 expression ( Figures S3-S5 ). Just two loci were expressed in all tested strains across all conditions: the 233 housekeeping gene rpsL (CT=25.3±1.97) and mexB (CT=29.0±2.14). oprD was expressed in all strains 234 except SCHI0039.S.1 grown in LB+NaCl. In contrast, ampC, and mexC, mexE, and mexY were 235 expressed in 1, 23, 26, and 2 of the 31 tested strains, respectively. Genetic analysis of all qPCR-236 targeted loci confirmed 100% primer and probe matches in those strains with genomic data, thereby 237 ruling out assay failure as a cause of undetectable expression. 238

Unexpectedly, there was no concordance between in silico AMR predictions and qPCR results for 239 strains grown under any of the tested conditions. SCHI0030.S.2 and SCHI0030.S.3, which were 240 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270419 doi: medRxiv preprint predicted to upregulate ampC through a previously undocumented AmpD frameshift variant (P42fs), 241 exhibited negligible or no ampC expression when grown in LB broth or LB+NaCl ( Figures S3 and S4) . 242

In contrast, SCHI0010.S.1, which does not encode any known chromosomal variant associated with 243 ampC upregulation (Table 1) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270419 doi: medRxiv preprint Correlation of qPCR results with antibiotic treatment (Table 1) identified that sputum ampC 265 expression levels were a good indicator of current β-lactam use, with 4/5 sputa with elevated ampC 266 expression collected from participants contemporaneously receiving β-lactams (SCHI0002_D8, 267 SCHI0010_D7, SCHI0013_D4, and SCHI0018_D8). Notably, 2/3 sputa (SCHI0002_D8 and 268 SCHI0013_D4) obtained from participants being treated with MEM, either with or without CAZ, 269 overexpressed ampC at high levels (6.7-15x); in contrast, ampC expression was only moderately 270 upregulated (1.7-1.9x) in two sputa (SCHI0010_D7 and SCHI0018_D8) from participants on CAZ but 271 not MEM (Table 1; Figure 2 ). ampC was downregulated or not expressed in eight sputa ( Figure 2 ) -of 272 these, four were collected from participants receiving no antibiotics at the time of collection, three 273 were receiving antibiotics other than β-lactams, and just one (SCHI0002_D329) was receiving CAZ 274 and MEM at the time of sputum collection (Table 1) . 275 SCHI0030, who received intravenous TOB and aztreonam for 15 days, provides an interesting case 285 study for observing AMR gene expression dynamics before, during, and after antibiotic treatment 286 (Table 1) . Although TOB has previously been shown to induce MexXY-OprM expression in CF sputa 287 (20), we unexpectedly did not observe AMR gene expression changes in SCHI0030 sputa ( Figure 2) . 288

Five sputa from other CF participants also showed limited or no mexY expression. In comparison, 289 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270419 doi: medRxiv preprint mexY was significantly upregulated in 4/5 COPD sputa (Figure 2) , none of whom have ever received 290 TOB (Table 1) . 291

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270419 doi: medRxiv preprint

Here, we developed and validated two multiplex qPCR assays for the simultaneous detection of 293 altered AMR locus expression in the ESKAPE pathogen, P. aeruginosa. When run in multiplex format, 294 our qPCRs showed very good to excellent LoD and LoQ values. qPCRs can be used both on P. 295 aeruginosa cultures and directly on human RNA-depleted sputa, the latter of which provides in vivo 296 expression profiling that overcomes transcriptional bias introduced with in vitro culture (20). 297

Building upon the pioneering work of Martin and colleagues, who first reported limited correlation 298 in ampC and mexX expression between sputa and corresponding derived isolates (20), we also 299 observed poor concordance between in vivo and in vitro expression profiles across six tested AMR 300 loci. Further, we found surprisingly poor correlation between in silico-predicted and in vitro AMR 301 gene expression. These findings raise questions about the clinical utility of in vitro antimicrobial gene 302 expression profiling and highlight the need for more work in this critical area of AMR research. 303

AmpC-driven AMR. We found that sputum ampC expression correlated well with contemporaneous 304 β-lactam treatment. In particular, two CF participants (SCHI0010 and SCHI0018) receiving CAZ but no 305 other β-lactams overexpressed ampC at moderate levels (1.7-2x); this overexpression increased to 306 6.7-15x in two other participants (SCHI0002 and SCHI0013) receiving MEM (Table 1; Figure 2 ). 307

Carbapenems such as MEM can be potent ampC inducers (63) and can remain effective even when 308 ampC expression is elevated (25), whereas cephalosporins such as CAZ are relatively weak inducers 309 of ampC and are readily hydrolysed by this enzyme (25). Our findings confirm that MEM can act as a 310 strong inducer of ampC expression in vivo. In light of this, we recommend that P. aeruginosa 311 infections should not simultaneously be treated with carbapenems and cephalosporins due to 312 potential ampC induction, which would render cephalosporin (and likely other β-lactam) antibiotics 313 ineffective (25). In contrast, eight sputa exhibited downregulated or no ampC expression (Figure 2) , 314 seven of which were taken from participants either not on antibiotics or not receiving β-lactams at 315 the time of sample collection, which likely explains the lack of β-lactam-driven ampC selection 316 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270419 doi: medRxiv preprint pressure. Of note, two COPD sputa, SCHI0109 and SCHI0050_D3, showed ampC upregulation (1.7-317 3.5x), despite neither participant receiving contemporaneous β-lactam therapy. Whilst the basis for 318 this upregulation is unknown, we speculate that β-lactam use in these participants would be 319 ineffective for P. aeruginosa eradication. Taken together, our results demonstrate that routine ampC 320 qPCR testing of P. aeruginosa-positive specimens is a useful diagnostic for monitoring in vivo 321 cephalosporin efficacy, enabling more rapid treatment shifts in instances where ampC is 322 upregulated. 323

Unlike sputa, almost all derived isolates failed to express ampC when grown in three different liquid 324 media. The exception was the derived isolate from CF participant SCHI0010. In LB broth, 325 SCHI0010.S.1 exhibited ampC hyper-expression (15x relative to SCHI0070_D2, and 43x relative to 326 PAO1; Figure S3 ), yet the corresponding sputum showed only modest ampC upregulation (1.7x; 327 Figure 2 ). This finding was unexpected as SCHI0010.S.1 does not encode any known chromosomal 328 variant associated with ampC upregulation (Table 1) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270419 doi: medRxiv preprint Expression of ampC was also undetectable in the MDR strain, SCHI0002.S.9, across the three in vitro 342 conditions ( Figures S3-S4) . Whilst this observation is consistent with the lack of predicted ampC 343 dysregulation in the SCHI0002.S.9 genome, it does not reflect the AMR phenotype of this strain, 344

which was resistant to all six tested penicillin, cephalosporin, and carbapenem antibiotics (Table 1) . 345

In addition, the corresponding SCHI0002_D8 sputum displayed the greatest ampC upregulation (15x; 346

Figure 2), probably due to contemporaneous CAZ and MEM treatment (Table 1 ). One possible 347 explanation for these spurious results is that high sputum ampC levels are conferred by an un-348 retrieved P. aeruginosa strain (20), as supported by two distinct AMR phenotypes and genotypes 349 isolated from SCHI0002_D8, SCHI0013_D4, and SCHI0030_D50 sputa (Table 1) Efflux-mediated AMR. mexB, mexC, mexE and mexY represent the RND efflux pumps most 359 frequently associated with AMR and MDR in P. aeruginosa (23, 25). As most CF participants were 360 being treated with anti-pseudomonal antibiotics at the time of sputum collection, and many of their 361 derived isolates encode key mutations associated with altered RND efflux pump expression (Table  362 1), we expected upregulation of these four efflux pumps in CF sputa. It was therefore surprising that 363 mexC was the only efflux system that demonstrated modest (1.7-2.1x) upregulation in a few patients 364 (2/9 CF sputa), whereas the other RND efflux systems were largely downregulated, or switched off 365 entirely, in CF sputa (Figure 2) . Also surprising was that most COPD sputa showed good expression of 366 these loci, despite only two COPD participants contemporaneously receiving anti-pseudomonal 367 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270419 doi: medRxiv preprint antibiotics, and almost no AMR phenotypes or efflux pump expression-altering genotypes in the 368 derived COPD isolates (Table 1) . This difference between diseases was most apparent for mexE and 369 mexY, which were significantly downregulated in CF but not COPD sputa (Figure 1 ). Although our 370 dataset is small, these observations suggest that RND efflux pump expression, and particularly mexE 371 and mexY expression, may not be required for chronic P. aeruginosa persistence in CF airways. This 372 finding contradicts prior in vitro work suggesting that MexXY-OprM efflux pump upregulation is 373 necessary for P. aeruginosa survival in the CF lung (73). We further postulate that the MexEF-OprN 374 and MexXY-OprM RND efflux pumps may have a minimal role, if any, in conferring AMR in P. 375 aeruginosa in vivo. mexE and mexY qPCR testing across a larger CF and COPD sputum panel is 376 needed to determine to veracity of our findings. 377

One possible explanation for efflux pump downregulation in CF sputa is that the CF cohort all 378 harboured chronic P. aeruginosa infections, whereas the COPD cohort potentially only had transient 379 (i.e. acute) infections. Like virulence factors (74), RND efflux pump expression may be upregulated 380 during the acute phase but then downregulated once P. aeruginosa transitions to a chronic lifestyle, 381 the latter of which is characterised by biofilm formation and reduced metabolic activity (25, 75) . In 382 support of this hypothesis, longitudinal sputa collected from CF participant SCHI0030 just prior, 383 during, and after a 15-day course of intravenous TOB and aztreonam treatment showed virtually no 384 change in RND efflux pump expression, with all AMR genes (including mexY) downregulated ( Figure  385 2) despite the aminoglycoside onslaught. In addition, one of two SCHI0030 strains obtained 35 days 386 after antibiotic cessation was fully susceptible to all 11 tested antibiotics, including TOB, hinting at 387 insufficient antibiotic penetration due to biofilm. As ours is one of the few studies to investigate P. 388 aeruginosa AMR gene expression in vivo, and the first to assess COPD sputa, more work is required 389 to verify these hypotheses, as there remains stark limitations in our understanding of the is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270419 doi: medRxiv preprint transition from acute infection to chronic persistence. We anticipate that our multiplex assays will 394 be a valuable tool for such studies. 395

Analysis of RND efflux expression among the CF-derived isolates encoding predicted RND efflux 396 upregulation revealed that almost none demonstrated increased efflux pump expression in vitro 397 ( Figures S3-S5) . Curiously, the MDR and hypermutated isolate SCHI0010.S.1, which does not encode 398 any known mutations associated with RND efflux pump upregulation, exhibited mexB (5.3x), mexC 399

(1.7x), mexE (1.5x), and mexY (28x) overexpression when grown in LB, although not when grown in 400

LB+NaCl or the 5-antibiotic cocktail (Figures S3-S5) . These results indicate that there are growth-401 specific requirements associated with upregulation of these genes. Furthermore, these observations 402 collectively indicate that in vitro efflux pump expression is not a good proxy for AMR phenotype, as 403 our CF-derived P. aeruginosa isolates demonstrate extensive MDR, yet we were unable to reproduce 404 their expected gene expression alterations in vitro. Our results contradict other in vitro experiments 405 reporting RND efflux pump hyper-expression as a major contributing factor to AMR development in 406 CF airway-derived P. aeruginosa (34, 39) . Caution should thus be taken when attempting to correlate 407 predicted AMR phenotypes with in vitro RND efflux pump expression profiles due to considerable 408 AMR gene expression changes exhibited under different culture conditions. 409

OprD-mediated AMR. As with the other AMR loci, we saw an unexpectedly poor correlation 410 between in vitro and in vivo oprD expression. Whereas 17/19 in vitro cultures expressed oprD at high 411 levels ( Figures S3-S5 ), 9/9 CF and 2/5 COPD sputa exhibited no detectable oprD expression (Figure  412 2). This finding strongly suggests that oprD downregulation is a common, and potentially dominant, 413 adaptive in vivo trait in chronic P. aeruginosa infections. Another noteworthy observation is that in 414 vivo oprD downregulation was not strictly associated with contemporaneous carbapenem use, as 415 only three of the CF sputa were obtained during carbapenem treatment, and none of the COPD 416 participants had ever received carbapenems. We posit that this adaptive mechanism may provide a 417 rapid, efficient, and effective way for P. aeruginosa to evade carbapenems in lieu of encoding 418 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270419 doi: medRxiv preprint functional oprD loss. In support of this hypothesis, two prior studies reported decreased oprD 419 expression as a cause of carbapenem AMR in 19/33 (58%) (77) and 39/117 (33%) (78) clinical 420

isolates. However, another study showed that in vitro oprD downregulation in carbapenem-resistant 421 isolates is a rare event, occurring in just 5/40 (13%) isolates (34). As our study illustrates, the 422 markedly different oprD expression profiles observed among studies may reflect differing in vitro 423 growth conditions; nevertheless, these in vitro findings show that P. aeruginosa can modulate its 424 oprD expression to confer carbapenem AMR. Like ampC, our oprD results indicate that there may be 425 great clinical value in characterising in vivo oprD expression to rapidly identify P. aeruginosa 426 infections that are recalcitrant to carbapenem therapy. 427

Concluding remarks. Our results add further weight to growing concerns about the relevance of in 428 vitro AMR research, particularly in vitro gene expression analysis, in clinical practice (79, 80). Due to 429 poor correlation between in vitro AMR testing and treatment outcomes in CF, empirical antibiotic 430 selection remains the preferred option due to better patient responses (72). Our findings confirm 431 that alternative approaches must be explored that minimise the transcriptional biases introduced 432 during culture (81) to better reflect in vivo P. aeruginosa gene expression (79). We recommend that, 433 wherever possible, gene expression of clinical specimens (e.g. sputum) be tested alongside cultured 434 isolates (20). This information will greatly improve our understanding of the shortcomings of in vitro 435 AMR testing whilst aiding in clinical decision making, providing more targeted treatment strategies, 436 enhancing antimicrobial stewardship, and improving patient outcomes. 437 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Tables 447 Table 1 . Pseudomonas aeruginosa-positive sputa, corresponding derived isolates, and disc diffusion profiles across 11 anti-pseudomonal antibiotics 448 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270419 doi: medRxiv preprint Table 1 for 478 details). Error bars, standard deviation. †Participants receiving non-pseudomonal antibiotics at the 479 time of sputum collection. 480 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 4, 2022. ; https://doi.org/10.1101/2022.02.03.22270419 doi: medRxiv preprint

Resistance to antibiotics: Are we in the post-antibiotic era? Archives of 482

Economic burden of antibiotic resistance in 484 ESKAPE organisms: a systematic review

Emerging strategies to 486 combat ESKAPE Pathogens in the era of antimicrobial resistance: A review

How to manage Pseudomonas 489 aeruginosa infections

Antibiotic resistance in Pseudomonas aeruginosa -491

Mechanisms, epidemiology and evolution

Pseudomonas aeruginosa: All 493 roads lead to resistance

Tackling the threat of antimicrobial 495 resistance: From policy to sustainable action

Antimicrobial resistance: Tackling a crisis for the health and wealth of 497 nations

Tackling antimicrobial resistance in the shadow of COVID-19

Antibiotic resistance -the need for global solutions

Genome-based prediction of bacterial antibiotic resistance

Practical issues in implementing whole-507 genome-sequencing in routine diagnostic microbiology

Rapid fluoroquinolone 510 resistance detection in Pseudomonas aeruginosa using mismatch amplification mutation 511 assay-based real-time PCR. medRxiv

Carbapenem 513 resistance in cystic fibrosis strains of Pseudomonas aeruginosa as a result of amino acid 514 substitutions in porin OprD

516 Insertion and deletion evolution reflects antibiotics selection pressure in a Mycobacterium 517 tuberculosis outbreak

Copy number 520 change of the NDM-1 sequence in a multidrug-resistant Klebsiella pneumoniae clinical 521 isolate

High-level resistance to meropenem in clinical isolates of Pseudomonas aeruginosa in 524 the absence of carbapenemases: role of active efflux and porin alterations

Sarovich 527 DS. 2021. Molecular epidemiology of third-generation cephalosporin-resistant 528

Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in 533 Burkholderia pseudomallei

Expression of Pseudomonas aeruginosa antibiotic 536 resistance genes varies greatly during infections in cystic fibrosis patients

Rapid evolution 542 and host immunity drive the rise and fall of carbapenem resistance during an acute 543 Pseudomonas aeruginosa infection

OprD mutations and inactivation, expression of efflux pumps and AmpC, 545 and metallo-beta-lactamases in carbapenem-resistant Pseudomonas aeruginosa isolates 546 from South Korea

Overexpression of AmpC and efflux pumps in 549 Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on 550 resistance in a Spanish multicenter study

Development and validation of a triplex quantitative real-time PCR assay to detect efflux 553 pump-mediated antibiotic resistance in Burkholderia pseudomallei

Pseudomonas aeruginosa: Resistance to the max

Stepwise upregulation of the Pseudomonas 557 aeruginosa chromosomal cephalosporinase conferring high-level beta-lactam resistance 558 involves three AmpD homologues

Development of carbapenem 560 resistance in Pseudomonas aeruginosa is associated with OprD polymorphisms, particularly 561 the amino acid substitution at codon 170

Emergence and impact of oprD 564 mutations in Pseudomonas aeruginosa strains in cystic fibrosis

Alterations in the GyrA and GyrB subunits of 566 topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-567 resistant clinical isolates of Pseudomonas aeruginosa

Expression of the multidrug 569 resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator 570 of operon expression

572 Novobiocin binding to NalD induces the expression of the MexAB-OprM pump in 573 Pseudomonas aeruginosa

Characterization of MexT, the regulator of the 575

OprN multidrug efflux system of Pseudomonas aeruginosa

MexXY multidrug efflux system of Pseudomonas 578 aeruginosa

Role of efflux pumps: MexAB-OprM and MexXY

OprD porin in non-metallo-beta-lactamase producing Pseudomonas aeruginosa isolated 582 from cystic fibrosis and burn patients

Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type 585 multidrug-resistant strains of Pseudomonas aeruginosa

MexCD-OprJ multidrug efflux system of 587 Pseudomonas aeruginosa: Involvement in chlorhexidine resistance and induction by 588 membrane-damaging agents dependent upon the AlgU stress response sigma factor

Characterization of the MexC-MexD-OprJ Multidrug Efflux System in mexA-mexB-592 oprM Mutants of Pseudomonas aeruginosa

Role of efflux pumps and mutations in genes for 594 topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains

Expression of the MexXY efflux pump in amikacin-resistant 597 isolates of Pseudomonas aeruginosa

Genomic diversity and antimicrobial resistance of Prevotella spp. isolated 600 from chronic lung disease airways

Determination of bacterial load by 602 real-time PCR using a broad-range (universal) probe and primers set

A one-step microbial DNA 605 extraction method using "Chelex 100" suitable for gene amplification

608 Identification of Pseudomonas aeruginosa by a duplex real-time polymerase chain reaction 609 assay targeting the ecfX and the gyrB genes

611 Epidemiology and treatment of multidrug-resistant and extensively drug

Pseudomonas aeruginosa infections

Substrate 614 specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas 615 aeruginosa

Efflux pump induction by quaternary ammonium compounds and fluoroquinolone resistance 618 in bacteria

mexEF-oprN multidrug 620 efflux operon of Pseudomonas aeruginosa: Regulation by the MexT activator in response to 621 nitrosative stress and chloramphenicol

Use of several inducer and substrate antibiotic 623 combinations in a disk approximation assay format to screen for AmpC induction in patient 624 isolates of Pseudomonas aeruginosa, Enterobacter spp., Citrobacter spp., and Serratia spp

The mismatch repair system (mutS, mutL and uvrD 627 genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring 628 mutants

636 Deciphering the resistome of the widespread Pseudomonas aeruginosa sequence type 175 637 international high-risk clone through whole-genome sequencing

The resistome of Pseudomonas aeruginosa in relationship to phenotypic susceptibility

Genomics and susceptibility profiles of extensively drug-resistant Pseudomonas aeruginosa 647 isolates from Spain

Within-host whole genome analysis of an antibiotic resistant Pseudomonas 650 aeruginosa strain sub-type in cystic fibrosis

Quantitative real-time PCR assay for the rapid identification of the 653 intrinsically multidrug-resistant bacterial pathogen Stenotrophomonas maltophilia

Development and validation of Burkholderia pseudomallei-specific real-659 time PCR assays for clinical, environmental or forensic detection applications

Key aspects of analytical method validation and linearity evaluation

Analysis of relative gene expression data using real-time 664 quantitative PCR and the 2(-Delta Delta C(T)) Method

Taking the next-gen 666 step: Comprehensive antimicrobial resistance detection from Burkholderia pseudomallei

Molecular mechanisms of β-669 lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical 670 strains

Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas 673 aeruginosa isolates from cystic fibrosis patients

Functional characterization of the NfxB repressor of the mexCD-676 oprJ multidrug efflux operon of Pseudomonas aeruginosa

Beta-Lactamases in laboratory and clinical resistance

Gene-gene interactions dictate 681 ciprofloxacin resistance in Pseudomonas aeruginosa and facilitate prediction of resistance 682 phenotype from genome sequence data

Penicillin-binding protein 3 is a common adaptive target 685 among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with β-686 lactams

Mutations in gene fusA1 as a novel mechanism of 688 aminoglycoside resistance in clinical strains of Pseudomonas aeruginosa

691 Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of 692 Pseudomonas aeruginosa

Differential beta-lactam resistance response 694 driven by ampD or dacB (PBP4) inactivation in genetically diverse Pseudomonas aeruginosa 695 strains

Pseudomonas aeruginosa evolutionary 697 adaptation and diversification in cystic fibrosis chronic lung infections

Chronic 700 colonization by Pseudomonas aeruginosa of patients with obstructive lung diseases: cystic 701 fibrosis, bronchiectasis, and chronic obstructive pulmonary disease

Van den Bossche S, De Broe E, Coenye T, Van Braeckel E, Crabbé A. 2021. The cystic fibrosis 707 lung microenvironment alters antibiotic activity: Causes and effects

Efflux 709 unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients

A signaling network 712 reciprocally regulates genes associated with acute infection and chronic persistence in 713 Pseudomonas aeruginosa

715 Stratified growth in Pseudomonas aeruginosa biofilms

The many faces of Pseudomonas aeruginosa in chronic obstructive 717 pulmonary disease

Interplay of efflux system, ampC, and oprD 719 expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates

Carbapenem resistance mechanisms in 722 Pseudomonas aeruginosa clinical isolates

Gene expression of Pseudomonas aeruginosa in a 725 mucin-containing synthetic growth medium mimicking cystic fibrosis lung sputum

Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived 729 from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions

Use of artificial 732 sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions 733 more relevant to the cystic fibrosis lung